Details of the Drug Reposition

General Information of This Drug (ID: DM4LSPN)

• Drug Name: Ibudilast (DM4LSPN)
• Synonyms: Eyevinal; Ibudilastum; Ketas; Ibudilastum [Latin]; Ke Tas; AV 411; I 0157; KC 404; AV-411; Ibudilast [INN:JAN]; KC-404; Ketas (TN); MN-166; Ibudilast (JAN/INN); 1-(2-Isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; 2-methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one; 3-Isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Castleman's disease	DISVC11M	4B2Y	Approved	[1]

5 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Alcohol dependence	DIS4ZSCO	6C40.2	Phase 2	[2]
Opioid dependence	DIS6WEHK	6C43.2Z	Phase 2	[2]
Methamphetamine dependence	DIS1UU1B	6C46.2	Phase 2	[2]
Multiple sclerosis	DISB2WZI	8A40	Phase 2	[3]
Amyotrophic lateral sclerosis	DISF7HVM	8B60.0	Phase 2	[4]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Asthma	DISW9QNS	CA23	Investigative	[5]

References

• [1] Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. Brain. 2023 Mar 1;146(3):898-911.